Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanomedicine: Will It Get Big?

This article was originally published in Start Up

Executive Summary

Big drugmakers will be watching closely to see if second-generation nanomed companies can program small particles to pack big pharmaceutical effects. We profile four start-ups that hope to show that they can: Blend Biosciences, Kala Pharma, Qualiber Technologies, and Uroboros Technologies.

You may also be interested in...

U.K.’s Midatech Develops Transbuccal Insulin Using Gold Nanoparticles

The biocompatible gold nanoparticle technology being developed by the U.K. biotech can be used to carry insulin quickly to its site of action, and is also being evaluated with GLP-1 agonists and oncologics.

AstraZeneca Leaps Into Nanomedicine With Bind Cancer Deal

AstraZeneca signs on with Bind to develop a nanotechnology-based, targeted kinase inhibitor that could be used in a number of liquid and solid cancers. For Bind, the news is highly validating as the company’s third deal with a major biopharma in 2013.

Bind Lands Nanoparticle Development Deal With Pfizer

The nanoparticle biotech has signed an agreement with Pfizer to develop an undisclosed number of small molecules that will use the Accurins technology to make the particles easier to use in hard to treat diseases.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts